GUOBANG PHARMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.66 CNY | +1.15% |
|
+2.46% | -5.13% |
| 15/04 | Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 27/01 | Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
| Sales 2024 * | 7.09B 979M 81.67B | Sales 2025 * | 8.06B 1.11B 92.89B | Capitalization | 9.25B 1.28B 107B |
|---|---|---|---|---|---|
| Net income 2024 * | 991M 137M 11.42B | Net income 2025 * | 1.21B 167M 13.9B | EV / Sales 2024 * | 1.31 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.15 x |
| P/E ratio 2024 * |
9.44
x | P/E ratio 2025 * |
7.7
x | Employees | 4,231 |
| Yield 2024 * |
3.78% | Yield 2025 * |
4.44% | Free-Float | 28.69% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.15% | ||
| 1 week | +2.46% | ||
| 1 month | +7.21% | ||
| 3 months | +18.49% | ||
| 6 months | -15.17% | ||
| Current year | -5.13% |
1 week
16.11
16.83
1 month
14.9516.93
Current year
13.0117.89
1 year
13.0122.99
3 years
13.0147.90
5 years
13.0147.90
10 years
13.0147.90
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Da Gong
DFI | Director of Finance/CFO | 56 | - |
Shi Xue Liao
PSD | President | 49 | - |
Jia Jun Qiu
CHM | Chairman | 59 | 01/96/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Chuan Ren
BRD | Director/Board Member | 64 | 18/19/18 |
Xiao Ming Wu
BRD | Director/Board Member | 69 | 18/19/18 |
Shi Xue Liao
PSD | President | 49 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 16.66 | +1.15% | 6,632,505 |
| 29/24/29 | 16.47 | +1.29% | 5,519,365 |
| 26/24/26 | 16.26 | +0.37% | 5,223,572 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.66
CNY
Average target price
24
CNY
Spread / Average Target
+44.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.13% | 1.28B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 605507 Stock
